Improving Memory in Patients With Multiple Sclerosis
Interventions to Improve Memory in Patients With Multiple Sclerosis
What it found
The trial ended early for another reason (see below).
Reason given: Study terminated/withdrawn
What was tested
Treatment tested
- Donepezil
- Dextrose
Who could take part
MS (type not specified) · 18 to 56 · EDSS 0 to 6.5
Show the full criteria
Inclusion criteria
* MS as defined by the Poser criteria * Expanded Disability Status Scale (EDSS) score of 0 to 6.5 * Stable neurologic function for at least 30 days prior to study entry * Agree to continue all current medications for study duration * Rey Auditory Verbal Learning Test score in low normal range or below * Mini-mental status exam score of 26 or higher * Montgomery-Asberg Depression Scale scaled score of 14 or lower * Fluent in English
Exclusion criteria
* Use of anticholinergic or benzodiazepine medication * Change in dosage of medications judged to have the potential to impact cognitive function (e.g., antispasticity medications) within 2 weeks of study entry * Current alcohol or substance abuse * History of neurological or major medical problem that has a known effect on cognitive functioning * History of noncompliance * Visual or upper extremity impairment which precludes ability to participate in cognitive assessment
As registered. Criteria can change, so ask the trial team or your neurologist.
About this trial
In the sponsor's words
People with multiple sclerosis (MS) suffer from cognitive and other brain problems. This study will examine the effectiveness of the drug donepezil and of sugar water for enhancing memory in individuals with MS. Donepezil (also known as Aricept) has been FDA approved for improving memory and learning in individuals with Alzheimer's disease.
Papers
Background
Prosiegel M, Michael C. Neuropsychology and multiple sclerosis: diagnostic and rehabilitative approaches. J Neurol Sci. 1993 Apr;115 Suppl:S51-4. doi: 10.1016/0022-510x(93)90209-h.Background
Rudick R, Antel J, Confavreux C, Cutter G, Ellison G, Fischer J, Lublin F, Miller A, Petkau J, Rao S, Reingold S, Syndulko K, Thompson A, Wallenberg J, Weinshenker B, Willoughby E. Clinical outcomes assessment in multiple sclerosis. Ann Neurol. 1996 Sep;40(3):469-79. doi: 10.1002/ana.410400321.Background
Krupp LB, Sliwinski M, Masur DM, Friedberg F, Coyle PK. Cognitive functioning and depression in patients with chronic fatigue syndrome and multiple sclerosis. Arch Neurol. 1994 Jul;51(7):705-10. doi: 10.1001/archneur.1994.00540190089021.Background
Kujala P, Portin R, Revonsuo A, Ruutiainen J. Attention related performance in two cognitively different subgroups of patients with multiple sclerosis. J Neurol Neurosurg Psychiatry. 1995 Jul;59(1):77-82. doi: 10.1136/jnnp.59.1.77.
Loading reviews and guidelines…
Related trials
- Electromagnetic Immunotherapy Mapping and Cytokine Forecasting Study (
Phase 1 / Phase 2 · Enrolling by invitation
Still running
- ANTIBIOBONTA - Assessment of the interest of a peri-operative antibiot
Phase 3 · Not yet recruiting
Still running
- Ketamine for MS Fatigue
Early phase 1 · Completed
Paper found, not read
- Ketamine for Multiple Sclerosis Fatigue
Phase 2 · Running, not recruiting
Still running
- Ketamine for Treatment of MS Fatigue
Phase 1 / Phase 2 · Completed
Results posted, not judged
- Treatment of Pendular Nystagmus in OPT
Phase 4 · Completed
Paper found, not read
History
Started
Sept 1999
Finished
Aug 2002